N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=126 Herbal Treatment for Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score
Phase 2 N=70 Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
Rhinitis
Primary: Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8 — 6.53; 3.65; 6.57; 4.14 Score on scale
Phase 3 N=547 Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)
Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial
Primary: The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15 — -3.01…
N/A N=10 Acupuncture for Nasal Congestion in Allergic Rhinitis
Allergic Rhinitis
Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 4 N=60 A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis
Rhinitis, Allergic, Perennial
Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05
Phase 3 N=365 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis
Rhinitis, Allergic, Perennial · Allergic Rhinitis
Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Total Nasal Symptom Score (rTNSS) — -4.226; -2.728 Points on a scale — p=<0.0001
Phase 3 N=1,992 The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…
Phase 3 N=716 Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
Allergic Rhinitis
Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001
Phase 3 N=340 Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis · Hay Fever
Primary: Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period — -2.0; -1.0 units on a scale…
Phase 3 N=95 A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3) — 16.96; 21.42 Sum of scores*hours — p=0.038
Phase 2 N=617 Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS) — -1.19; -1.58; -1.68; -1.63 score on a scale
Phase 2 N=40 SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
Rhinitis
Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Phase 3 N=1,482 Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Nonseasonal
Primary: Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment — 4.67; 5.49 Score on a Scale — p=<0.001
Phase 3 N=1,365 Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
Perennial Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale
Phase 3 N=474 Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
Rhinitis, Allergic, Perennial
Primary: Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period — -2.5; -1.6 units on a scale — p=<0.001
Phase 4 N=62 ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)
Rhinitis, Allergic, Perennial
Primary: Mean Weekly Total 4 Symptom Score (T4SS) During the Treatment Period — 2.89; 3.15 units on a scale — p==0.667
Phase 3 N=302 Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline (Day 1) Over the Entire Treatment Period in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over 6 Weeks — -2.69; -3.95 Scores on a scale…
Phase 4 N=191 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
Allergic Rhinitis
Primary: Safety — 43; 39 adverse events
Phase 4 N=310 This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)
Seasonal Allergic Rhinitis
Primary: Changes in the Total Nasal Symptom Severity Score (TNSS) at 6 Hours After Dosage Administration on Day 1 — -2.01; -1.86 score on a scale — p=0.625
Phase 2 N=606 Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSS — -3.57; -2.31; -2.96; -1.48 score on a scale
Phase 2 N=217 Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Allergic Rhinitis · Conjunctivitis
Primary: Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at…
Phase 3 N=327 Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
Perennial Allergic Rhinitis
Primary: Total Preference Composite Score Assessed at the End of the Study. The Total Preference Score is the Standardized Sum of 17 Individual Preference Items — 68.3 scores on…
Phase 4 N=358 A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)
Rhinitis, Allergic, Perennial and Seasonal · Rhinitis, Allergic
Primary: Mean Change From Baseline in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over the First 2 Weeks Treatment Period — -1.95; -3.18; -3.28 Scores on a scale…
Phase 3 N=626 Assessment of Fluticasone Propionate on Ocular Allergy Symptoms
Allergic Rhinitis · Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS) — -0.91; -0.63 Score on a scale — p=0.0024
N/A N=45 Nasal Allergen Challenge in Rhinitic Subjects
Asthma · Allergic Rhinitis
Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils
Phase 2 N=31 A Novel Biologic Therapy for Perennial Allergic Rhinitis
Allergic Rhinitis
Primary: Daily Combined Score (DCS) — -4.41; -1.61 DCS (daily combined score)
Phase 2 N=71 A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
Rhinitis, Allergic, Perennial and Seasonal
Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 of Each Treatment Period — 6.030; 4.189; 4.500…